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The presence in the blood of small particles, probably platelets, 
was observed by Donne in 1842 and established by Bizzozero in 1882 (quoted 
from Odell and Knisely, 1962). Indirect evidence suggested that the 
platelets were formed in the megakaryocytes of the bone marrow and this 
has been confirmed by bone marrow culture (Albrecht, 1957). Platelet 
life span in animals was estimated indirectly by measuring the time for 
the platelet count to return to normal after bleeding (Bedson,1923) and in 
man by observing the effect of platelet transfusion into thrombocytopenic 
patients (Hirsch and Gardner, 1951). Further indirect evidence came from 
study of the effects of, and the recovery from, therapeutic or accidental 
irradiation. These studies suggested a platelet life span of from 2 to 
10 days. 
In the 1950s the introduction of radioisotopes gave a new 
impetus to the measurement of the survival of the cells of the blood. 
The measurement of the survival of red blood cells is now commonly used 
in the investigation of patients with haemolytic anaemia. Surface counting 
over the liver and spleen, following the administration of radioactively 
labelled red cells, is known to be of value in the selection of such patients 
for splenectomy. Platelet survival using isotopes has been studied in 
several centres (Aas and Gardner, 1958; Davey and Lander, 1963) but 
there are few reports in the literature from this country (Alfos, Field 
and Ledlie, 1959). There have been two main fields of interest, the 
thrombocytopenias (Cohen, Gardner and Barnett, 1961; Najeon, Ardaillou, Caen, 
Larrieu and Bernard, 1963) and atheroma (Murphy and Mustard, 1962). The 
present work was undertaken to develop a method of estimating platelet 
survival in order to define more closely the role of the spleen in the 
production of thrombocytopenia, and to assess whether the measurement of 
platelet life span with surface counting could be used to predict the 
response to splenectomy of patients with idiopathic thrombocytopenic 




Two platelet labels have been used, sodium chromate with 
incorporated 51Cr and diisopropylphosphoro -fluoridate (DFP) in which 
the phosphorus is 
32 
P. Some of the advantages and disadvantages of 
these two methods are outlined in Table 1. 
Sodium Chromate Method: 
We have used a modification of the method proposed by Aas 
and Gardner (1958) for the in vitro labelling of platelets with sodium 
chromate. One pint of blood is collected from the patient or from an 
ABO Rh compatible donor into a Fenwal plastic pack in which the anticoagulant 
is disodiumethylenediamine tetracetic dihydrate (EDTA) in saline. The 
whole blood is centrifuged at 2oC for 20 minutes, at 1000 r.p.m. in an IvISE 
Major centrifuge. The platelet rich plasma is then transferred with a 
plasma extractor to a sterile siliconed MRC glass bottle which is spun at 
2000 r.p.m. for 15 minutes. The plasma is withdrawn and the platelet 
"button" resuspended in 8 -10 ml. of normal saline. 250 - 400 p.c. of sodium 
51chromate 
are added and the mixture incubated at 25°C for one hour. 
Approximately 80 ml. of normal saline are added and the mixture centrifuged 
o 
at 4 C for 10 minutes at 2000 r.p.m. The supernatant is kept for 
measurement of its radioactivity. The platelet "button" is again 
resuspended in normal saline, to a volume of about 20 ml. A small aliquot 
is retained for measurement of its radioactivity and the remainder is 
given by intravenous injection to the patient to be studied. The amount 
of radioactivity varies from 20 -100 pc. 
Comments on Labelling Procedure: 
1. Equipment: Plastic packs and siliconed glassware are used 
to minimise the loss of platelets (Aas and Gardner, 1958; Najean et al, 1963). 
The recovery of platelets from the original pint of blood varied from 30 
to 80% with an average of 60 %. Higher values than this were achieved at 
the expense of greater contamination with red cells. 
3. 
2. Anticoagulant: The anticoagulant used was EDTA as most 
workers have shown a higher recovery of platelets with this, than when 
using the normal acid- citrate -dextrose (ACD) mixture as anticoagulant. 
It now appears that a preferable anticoagulant would be an acid- citrate- 
dextrose mixture with a higher concentration of citrate as proposed by 
Aster and Jand1 (1964). Platelets suspended in EDTA are niore spherical 
and clump less readily than with the normal A.M. But EDTA may damage 
platelets which are naturally more disc -shaped. The increased acidity 
of the citrate -enriched ACD mixture apparently allows the platelets to 
assume their normal disc shape without rendering them unduly "sticky ". 
The effect is a greater yield of platelets from the patient and much less 
sequestration. The present work was continued with EDTA to allow all 
the results to be comparable. 
3. Donor platelets: It is known that the platelets share 
the A and B antigens of the erythrocytes (Dausset, 1963). In all cases 
when donor platelets were used, the platelets were obtained from ABO 
Rh compatible blood. This does not exclude incompatibility due to other 
antigens but in no case was unexpected shortening of the platelet lifespan 
found except in two patients who had recently had multiple transfusions. 
4. Time of Incubation: We have _sound that when incubating at 
0 51 
25 C the uptake of sodium chromate increases up to 90 minutes (Fig. 1) 
and then diminishes. This agrees with the findings of Davey and Lander 
(1963) who found a linear increase with time (at 24°C) up to 40 minutes 
but disagrees with the observations of Aas and Gardner (1953) who found 
no increase after 15 minutes. 
5. Temperature of Incubation: The uptake of chromate by 
platelets incubated for 30 minutes increases as the temperature is raised 
to 37 
0 
C but falls thereafter (Fig. 2). Davey and Lander (1963) also 
reported increasing labelling efficiency up to 37oC but Aas and Gardner 
(1953) noted a decrease between room temperature (20-22°C) and 37°C. 
G. Chromium Concentration: Concentrations of chromium above 
L 
3 µgm. per 10 
10 
platelets diminishes labelling (Fig. 3). This agrees with 
the findings of other workers. 
7. Washing of Labelled Platelets: Initially this was done but 
the supernatant wash always contained less than 5% of the radioactivity 
bound to the platelets and usually less than 3 %. Thereafter washing was 
not performed but the addition of 80 ml. of normal saline to the incubating 
mixture before the final centrifugation of the platelet button allowed removal 
of more than 99% of the radioactivity not bound firmly to the platelets. 
8. Superinone: Initially, this compound, also known as Triton 
or WR -1339, was added to the saline used for suspension and washing of 
the platelets. It is a non -toxic, surface active substance believed to 
render platelets less sticky and thus facilitate re- suspension of platelets. 
In practice its use was found to be unnecessary. 
9. Efficiency of labelling: The uptake of sodium51chromate by 
the platelet fraction from one pint of blood varied from 12.5 to 40%. The 
higher values are obtained with high platelet yield and the lower 
efficiencies are seen when the platelet recovery is poor, when the 51Cr 
has a low specific activity, leading to a high concentration of chromate, 
or when the platelet fraction is contaminated with red cells, which have a 
much greater affinity for chromate. 
10. Determination of Platelet Bound Radioactivity: Two 1 ml. 
aliquots of the platelet infusion are taken. One is diluted in 200 ml. 
water. The other is washed in 1% ammonium oxalate which lyses contaminating 
red cells, thus releasing the haemoglobin -bound sodium51chromate into the 
supernatant. Thus the total radioactivity injected may be calculated and 
also the proportion of that radioactivity which is bound to platelets. 
11. Site of Binding of Chromate to Platelets: This is unknown. 
DFP Method: 
We have used this toxic compound in a dose of 100 µc. given by 
intravenous injection. It is obtained from Amersham dissolved in propylene 
glycol., with a high specific activity so that this amount of radioactivity 
is contained in an amount of the compound which is well below the toxic level 
Fig. 
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to the body. There were no untoward reactions to the substance. DFP 
binds irreversibly to esterases in the cell membrane and is a satisfactory 
in vivo label for red cells (Cohen and Warringa, 1954) and platelets 
(Leedsma and Cohen, 1956; Murphy and Mustard, 1962). Its main disadvantage 
is that the amount of red cell binding is much greater than platelet binding, 
necessitating careful separation of the platelets for counting. The 
amount of platelet bound radioactivity is too small to count in patients with 
severe thrombocytopenia. 
Preparation and Counting of Blood samples: 
Following labelling of the platelets, blood samples are taken 
one hour after infusion of the labelled platelets or DFP and daily therafter 
for up to 12 days. The volume initially was 20 ml. but latterly 10 - 15 ml. 
has been found to be adequate. The anticoagulant used is 2% EDTA. The 
platelets are separated by a modification of the silicone flotation technique 
of Morgan and Szafir (1961). Approximately 5 ml. of silicone mixture 
(85% MS 555 Hopkin and Williams and 15% MS 200/20 CS Hopkin and Williams) 
are added to the mixture of whole blood and EDTA, in a 50 ml. siliconed 
centrifuge tube. This is centrifuged at 1200 r.p.m. for 10 minutes in an 
MSE Major Refrigerated centrifuge. The specific gravity of the silicone 
mixture is 1.040 which is between the specific gravity of platelets and 









Platelet ' Platelet 
t/ / / /j< Red cell button button 
and platelets (Fig. 4). The platelet rich plasma also contains the lighter 
red cells which are reticulocytes and young cells, a few polymorphs and many 
lymphocytes. 51Cr labels red cells which are thus largely removed. DF32P 
labels polymorphs and red cells which are largely removed. Lymphocytes 
are not significantly labelled by DFP. The platelet rich plasma is 
pipetted into a clean siliconed 10 ml. centrifuge tube which is spun at 3000 
r.p.m. for 10 minutes. The supernatant plasma is removed and the platelet 
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button resuspended in 1% ammonium oxalate. The tube is again centrifuged 
at 3000 r.p.m. for 10 minutes, the supernatant discarded and the final 
platelet button resuspended in 3 ml. ammonium oxalate ready for counting 
if chromate is the label and ready for evaporation on to a planchet if 
the label is phosphoro -fluoridate. Contaminant red cells are lysed by 
the wash in ammonium oxalate which also removes most of the polymorphs 
not already separated. Further washing with 1% ammonium oxalate can be 
done. This is not necessary for 51Cr as the method used gives fairly 
high radioactive counts in the platelet fraction and little in the red 
cells but is usually required (three washes) when DFP has been used in 
order to obtain complete separation of the platelets from the red cells 
(which have a greater affinity for DFP). The above method gives a 100% 
yield of platelets. The figures found vary from 90 - 105% which is within 
the experimental error of counting (Dacie and Lewis, 1963). Many workers 
have related radioactive counts in the platelets to the actual number of 
platelets. Using the above method we have found that this is unnecessary 
and instead count the amount of radioactivity in the platelet fraction of 
a known volume of whole blood. We believe that the error of counting 
platelets (at least 10%) is greater than the error of separation of platelets 
by this method. 
Samples with 51Cr are counted in a standard well type 
scintillation counter. When DFP is the label the platelet fractions are 
evaporated to dryness under an infra -red lamp on aluminium planchets and 
counted under an end -window 13 counter. All samples from one patient 
are counted on the same day to obviate correction for different radioactive 
decay. If both labels are used 51Cr counting is carried out as described. 
The samples are then dried on planchets and their 13 counts determined. 
This count is corrected for activity due to 51Cr in order to obtain the 
"true" DFP count. Counting is carried out to allow an error of less than 
3 %. 
Surface Counting: 
This is carried out daily over the praecordium, liver and 
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spleen using a directional scintillation counter with fairly wide 
collimation. Counting is done for 3 - 10 minutes according to the rate 
of the count. In a few patients two matched scintillation counters 
connected to ratemeters and recorders have been used to give a continuous 
record immediately following infusion of the 51Cr labelled platelets. 
The sites for surface counting are as follows: praecordium - fourth left 
intercostal space at sternal edge; liver - ninth right intercostal space 
half -way between the anterior and mix -axillary lines; spleen- no standard 
position has been used. The one adopted is that which gives a maximum 
count for the patient. In patients with idiopathic thrombocytopenia for 
example, in whom the spleen is normal in size, the counter will be sited 
over the 10th -llth left intercostal space on the posterior axillary line. 
In patients with splenomegaly the positioning need not be as precise and 
is usually over the costal margin on the left anterior axillary line. 
Interpretation of Results: 
The maximum radioactivity in any platelet fraction of a patient 
is taken as 100% and the radioactivity of the other samples expressed as 
percentages of the maximum. This allows comparison of all results. 
Platelet lifespan is expressed as lifespan or extinction time, and is the 
time in days when the platelet -bound radioactivity is less than 5% of the 
maximum. The T2Cr or Ti DFP is not used because of doubt as to the exact 
shape of the survival curves. 
In the interpretation of surface counting data in studies with 
Na251Cr04 labelled red cells two factors are commonly accepted as important 
(Jandl, Greenberg, Yonemoto and Castle, 195G). The splenic sequestration 
index is the percentage increment in the spleen /praecordium ratio between 
the start of the survival study and the T2Cr. (The T2Cr is the time for half 
of the radioactivity to disappear from the blood). This value is not valid 
in platelet survival studies because of the early irreversible sequestration 
of some platelets in the spleen. The other index used is the spleen/liver 
ratio at T2Cr but the value of this is also questionable because of the 
sequestration noted above. The spleen/liver ratio and the splenic 
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sequestration index are easy to use because correction of the counts 
for radioactive decay is unnecessary. The spleen/liver ratio has been 
calculated in our patients. 
In an attempt to standardise the results for all patients and 
to assess the amount of radioactivity in the spleen, the surface counts 
over the spleen at TZCr have been corrected for decay and divided by the 
total amount of injected platelet -bound radioactivity in micro -curies. 
This is an arbitrary value, the results of which depend inter alia on the 
counting system used. The present one in this study gives a count of 
18 counts /second /micro -curie at a distance of 10 cm. from the crystal, 
with a background of 11 counts /second. A similar value has been used 
by Aster and Jandl (1964). The determination of injected platelet -bound 
radioactivity is discussed above (Sodium Chromate Method - Comment 10). 
Results: 
Normal Platelet Survival 
In Fig. 5 are shown the survival curves of 51Cr labelled 
platelets in two normal patients. On the left is illustrated the relative 
amounts of radioactivity in the component fractions of the blood samples. 
Usually there are insignificant counts in the red cells or plasma. 
However if the original platelet infusion is contaminated with red cells 
(which will also be labelled) the amount of activity in the red cells 
becomes very significant as the platelet activity falls. Therefore platelet 
fractions are counted and not whole blood. 
The radioactivity in the platelets falls in a curvilinear 
fashion and becomes negligible (less than 5% of the maximum) at lO days, 
the so- called extinction time. Eight normal subjects have had platelet 
survival times of 8 -12 days. Autologous and isologous platelets give 
similar results although we have no figures of direct comparison. 
For ease of comparing results the maximum platelet activity is 
taken as 100% and all other samples expressed as a percentage of this. 
This is demonstrated on the right of Fig. 5, in which the results from 
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another control subject are also seen. The second survival curve (J.M.) 
shows that the platelet activity is less one hour after infusion than after 
one day. This is believed to be due to sequestration of a large proportion 
of the injected platelets in the first 30 minutes after infusion (Davey 
and Lander, 1964; Aster and Jandl, 1964). A variable proportion of these 
sequestered platelets return to the circulation within 24 hours. Davey 
and Lander (1964) have made a most extensive study of the initial sequestration 
and believe that it occurs throughout the vascular bed but particularly in 
the liver, spleen and lungs. Surface counting by us has confirmed the 
importance of the liver and spleen as sites for sequestration but we have 
not observed significant counts over the lungs. 
Studies using DF32P gives very similar results to 51Cr. The 
survival curve is identical but occasionally the latter part of the curve 
shows some "tailing" (Fig. 6). This has been noted by Barkham (1966) and 
may be due to labelling of plasma proteins not removedby washing or to 
partial re- utilisation of the label. Platelet lifespan with DFP is also 
8 -12 days. 
Comparison of Labels: 
DF32P and 51Cr have been directly and simultaneously compared 
in 15 patients, 3 normal subjects, one patient with carcinoid syndrome, 
2 patients with spherocytosis, one patient with essential thrombocythaemia, 
3 with reticuloses, 3 with cirrhosis of the liver and portal hypertension, 
and 2 patients with idiopathic thrombocytoepnic purpura following splenectomy. 
The graphs of the survival of the platelets of 8 patients are shown in Fig. 6. 
There is excellent correlation. In some patients there is a tendency to a 
"tail" in the DF32P curves. Most of the 51Cr curves show more radioactivity 
on day 1 than 1 hour after infusion of the ]abelled platelets. 
On one occasion we have found a discrepancy between the results 
given by the two methods (Fig. 7). In this man with idiopathic thrombo- 
cytopenia before splenectomy the platelet count was 20,000 /cu.mm. and the 
platelet survival, estimated with 51Cr labelled donor platelets, was 
markedly shortened to 1 day. Following operation the platelet count 
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returned to normal and as expected, the survival of the patient's own 
platelets, labelled with DFP, was normal. However 51Cr labelled donor 
platelets showed continued shortening of platelet lifespan. This may 
have been due to iso- immunisation resulting from blood transfusion at 
time of operation or from the previous platelet infusion. 
Idiopathic Thrombocytopenic Purpura (ITP) 
Seventeen patients have been studied. Four had failed to 
respond to splenectomy and had persisting thrombocytopenia. Eleven 
patients were studied prior to splenectomy and six of them proceeded to 
splenectomy, which led to a remission in all. Platelet survival was also 
studied in two patients whose spleens had been removed some years before 
and who were in remission with normal platelet counts. The results are 
summarised in Table 2. In all donor platelet labelled with 51Cr were used. 
In three patients with thrombocytopenia and megakaryocyte 
hyperplasia in the marrow, the platelet survival was normal. These patients 
are of particular interest. In all other patients with thrombocytopenia 
pre- or post -splenectomy, the platelet survival was markedly reduced. Six 
of the patients with thrombocytopenia studied, proceeded to splenectomy and 
in all the platelet count returned to normal; in three the platelet survival 
was also measured after splenectomy and was normal. In all patients with 
normal platelet counts the platelet survival was normal. 
Thrombocythaemia and Thrombocytosis 
We have measured platelet survival in five patients who had 
increased platelet counts in the peripheral blood. In all the lifespan 
of the platelets was normal (Fig. 8). One patient had essential thrombo- 
cythaemia and four had thrombocytosis following removal of the spleen for 
thrombocytopenia dur to disseminated lupus erythematosus, spherocytosis 
(two patients) and traumatic rupture of the spleen. 
Hypersplenism 
Eighteen patients with large spleens and low white blood cell 
counts and platelet counts have been studied. The results and diagnoses 
11. 
are given in Table 3. The platelet survival was normal in all but two 
patients who had lymphoproliferative disorders. 
Aplastic Anaemia 
Two patients with this condition were studied and both had 
normal platelet lifespan. 
Surface Counting 
In the section on methods the interpretation of surface counting 
data is discussed. In Fig. 9 the data on patients with idiopathic thrombo- 
cytopenic purpura and hypersplenism and in normal subjects, are presented. 
The spleen /liver ratios in patients with ITP (six of whom subsequently had 
splenectomies performed with beneficial results) are not different from 
normal patients. Patients with hypersplenism have values which overlap 
normals but which are mostly higher. The calculated absolute spleen 
counts in patients with ITP are greater, relative to the infused radioactivity, 
than in patients with hypersplenism or normal subjects. It should be 
pointed out that the total radioactivity in the spleen in patients with 
splenomegaly will be relatively greater than in normal subjects or patients 
with ITP, as one is counting over a smaller proportion of the spleen in 
patients with splenomegaly. 
The actual liver counts /injected radioactivity are of course 
also higher in patients with ITP, and it is evident from these results 
that a greater proportion of the platelets infused are destroyed in the 
liver and spleen in patients with ITP than in normal subjects in whom the 
platelets may be destroyed throughout the vascular bed. 
In Fig. 10 are shown the results of surface counting and 
platelet lifespan measurements in 9 patients who had been subjected to 
splenectomy before study. Four had ITP and were "failad splenectomy", 
two had responded to removal of the spleen and three had the spleen 
removed for other reasons - spherocytosis, traumatic rupture and portal 
hypertension. Patients with ITP failing to respond to splenectomy, 
have a reduced survival of platelets associated with a high uptake by the 
liver. 
12. 
Tissue Measurements of Radioactivity 
Two patients with cirrhosis, portal hypertension and spleno- 
megaly died shortly after completion of platelet survival studies. The 
tissues of the body were analysed for radioactivity. There were small 
amounts of activity in all tissues but significant amounts only in the 
spleen, the liver and the bone marrow. 
Surface counts over the spleen and liver were compared with 
tissue counts in several patients with ITP who proceeded to splenectomy 
at which liver and splenic biopsies were obtained. The work of Aster 
and Jandl (1964) was confirmed in showing that the efficiency of counting 
over the spleen is four times that over the liver when the surface counts 
are compared with counts per gramme of tissue. 
Discussion: 
Methods 
The method for labelling of platelets with 51Cr involves 
several compromises. We have chosen 25oC and 60 minutes incubation 
time as values which allow adequate labelling but which do not cause damage 
to the platelets. The method of labelling with DF32P is a standard one 
but we believe that the separation of platelets from blood samples by silicone 
flotation followed by washing in 1% ammonium oxalate allows for optimum 
recovery of platelets and platelet -bound radioactivity and obviates platelet 
counting of separated fractions, which is both tedious and inaccurate. 
The unsatisfactory points of the methods are the extent of sequestration 
with 51Cr and the unsuitability of DF32P as a label in patients with 
severe thrombocytopenia. The sequestration is due to alteration of the 
properties of the platelets by the anticoagulant used, EDTA, perhaps by 
removal of magnesium Mg by chelation (Aster and Jandl, 1964). 
Further experience is intended with a modification of the usual acid - 




P in patients with platelet counts down to 30,000 /cu,mm. if counting 
techniques can be improved,perhaps by the use of liquid scintillation 
counting. 
13. 
We have little experience as to the extent of elution of 
the two labels from the platelets. However, we feel that if elution were 
an important factor, it would be unlikely to be identical with the two 
labels in which event there would not be good correlation between the two 
methods. Aas and Gardner (1958) found 40-70% elution in one hour from 
platelets labelled with Na2CrO4 and then incubated at room temperature in 
vitro, but believed that elution did not take place in vivo. We have 
not observed a significant leak of 51Cr from platelets labelled as 
described, and subsequently left at room temperature for up to 90 minutes 
after completion of preparation of the labelled platelets. 
Apart from the difficulty of interpretation of surface counting 
data following infusion of51Cr labelled platelets from blood anticoagulated 
with EDTA , the recovery of platelets in the peripheral blood is only 10 - 
60% of that injected, due also to sequestration of platelets. Aster and 
Jandl using EDTA obtained recoveries of only 5 to 30% but when a modified ACD 
anticoagulant was used, the recovery of platelets increased to 75 %. 
Normal Survival 
There has been considerable discussion as to the precise nature 
of the survival curves. Most of our survival curves are almost linear 
but a slight deviation from the straight line is evident in some. This 
curvilinear type of graph is in favour of death by senescence rather than 
the alternative theory of random destruction of platelets which would 
give an exponential type of curve. The problem has been studied in 
considerable detail, using DF32P, by Mustard, Rowsell and Murphy (1966) 
who have proposed a "multiple -hit" hypothesis, in which the lifespan of an 
individual platelet depends on the number of "insults" it sustains. If 
they are few the platelet will survive "normally" to 10 days; if they are 
many it will be used up in a day or two. The truth may be that most 
platelets normally "die" by senescence, and are thus directly comparable 
to red blood cells, but some may be destroyed earlier by virtue of their 
function such as maintaining the integrity of the endothelial surfaces. 
Mustard, Rowsell and Murphy (1966) have found in pigs that when the platelet 
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count is low, platelets infused will have a lifespan shorter than normal 
and this would support their "multiple -hit" hypothesis. But in two 
patients with aplastic anaemia and three patients with apparent idiopathic 
thrombocytopenic purpura, we have found a normal survival of infused 
platelets when the platelet count was very low indeed. Many patients 
with hypersplenism have normal platelet survival and thrombocytopenia. 
Therefore we do not believe that survival of platelets is largely dependent 
on the platelet count in the peripheral blood. 
Idiopathic Thrombocytopenic Purpura 
This condition is diagnosed by exclusion of other causes of 
thrombocytopenia, in the presence of a reduced platelet count and mega - 
karyocytic hyperplasia in the marrow. It has been suggested that it is 
an autoimmune condition in which the platelets are prematurely destroyed 
by antibodies, which are possibly produced in the spleen in cases responding 
to splenectomy. Techniques for demonstrating anti -platelet antibodies 
are technically very difficult and in the best hands give positive 
results in less than 50% of cases (Dausset, 1963; Cohen, Gardner and Barnett, 
1961). It the autoimmune hypothesis is correct the thrombocytopenia is 
due to shortened platelet lifespan. This has been demonstrated by several 
workers (Aas and Gardner, 1958; Cohen, Gardner and Barnett, 1961; Najean, 
Ardaillou, Caen, Larrieu and Bernard, 1963; Aster and Jandl, 1964). We 
have shown reduction of donor platelet lifespan in patients with idiopathic 
thrombocytopenic purpura and a return to normal after splenectomy. 
Because of the normal platelet survival found in patients with aplastic 
anaemia in whom there was as marked thrombocytopenia, we do not believe 
that the shortened platelet lifespan in patients with ITP is due to 
increased utilisation of platelets. If the platelets are prematurely 
destroyed in ITP following an immune reaction, then one would expect 
the survival curve to be exponential in nature as is seen with the red cells 
in acute autoimmune haemolytic anaemia. Unfortunately due to the initial 
partially reversible sequestration of platelets following infusion, the 
shape of the survival curve in the first day is extremely difficult to 
interpret and the platelet lifespan may be only 1 - 2 days. Present 
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techniques do not permit the use of DF32P to elucidate the nature of the 
survival curve as there is insufficient radioactivity in the platelet 
fractions of the blood. 
Thrombocythaemia and Thrombocytosis 
We have not found a prolonged platelet survival in any patient 
with an increased platelet count whether 51Cr or DF32P is used as the 
platelet label. Aster and Jandl (1964) reported normal survival of 
platelets labelled with 51Cr in a patient with essential thrombocythaemia. 
However Alfos, Ledlie and Field (1959) using DF32P claimed to show prolonged 
platelet lifespans in 3 patients with essential thrombocythaemia. We 
believe that the increased platelet count in patients with thrombocythaemia 
or post -splenectomy thrombocytosis is due to increased production and not 
prolonged platelet survival. 
Hypersplenism 
Cohen, Gardner and Barnett (1961) have reported normal platelet 
survivals in patients with hypersplenism. We have confirmed this except 
in two cases with lymphoproliferative disorders in which an alteration in 
the immune reactions of the lymphocytes might be expected to lead to the 
production of abnormal antibodies against the platelets. It is known that 
in these conditions autoimmune haemolytic anaemia may occur. The cause 
of the thrombocytopenia in patients with splenomegaly and normal platelet 
lifespans is not known. It has been postulated that the spleen, through 
a humoral factor, may inhibit marrow production. But no agent has been 
demonstrated and the marrow in our patients showed normal numbers of mega - 
karyocytes, confirming the report by Bouma, Veeger, Jansz, Woldring, Abels 
and Nieweg (1963). Recently it has been established that anaemia in 
patients with large spleens may in part be due to red cell pooling in the 
spleen (Toghill, 1964; Richmond and Donaldson, 1966). It is also known 
that in hypothermia reversible sequestration of platelets may occur in the 
liver and spleen (Boumaetal, 1963). Therefore it is postulated that the 
reduced platelet count in patients with splenomegaly and normal pláelet 
survival is due to sequestration of a proportion of the platelets in the 
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spleen. This is supported by the worm of Penny, Rozenberg and Firkin 
(1966) who, by perfusion of spleens removed surgically, demonstrated a 
pool of splenic platelets, the extent of which appeared dependent on 
spleen size alone. Our surface counting data showing high spleen /liver 
ratios also support this concept, and the ratios observed are artificially 
low as one is counting over a smaller proportion of the total splenic area 
in patients with splenomegaly, as opposed to normal subjects and patients 
with ITP. 
The cause of the splenomegaly appears to be immaterial. We 
have observed normal platelet survival, like Cohen et al (1961) in patients 
with cirrhosis, reticulosis and leukaemia. It has also been found in two 
patients with idiopathic tropical splenomegaly and one patient with kala- 
azar, and this is the first report of platelet lifespan measurements in 
these conditions. 
Surface Counting 
The initial rapid sequestration of platelets labelled with 
51 
Cr in the liver and spleen masks subsequent changes in the radioactivity 
of these organs and makes the interpretation of surface counting over them 
difficult, particularly in ITP when the platelet survival may be only 24 
hours. However, Najean et al (1963) reported that splenic localisation 
was uncommon in patients with idiopathic thrombocytopenic purpura, but 
when present, was associated with a good result from splenectomy. Patients 
not showing such localisation might or might not do well following removal 
of the spleen. Our data shows that although the spleen/liver ratio does 
not distinguish between normal subjects and patients with ITP, the absolute 
counts over the spleen, standardised for each patient, are higher than 
normal in such patients. Thus far all the patients studied before 
splenectomy have done well after operation and further experience is necessary 
before we shall know whether we shall be able to predict the response to 
operation. However the results do suggest that in patients with ITP a 
greater proportion of injected platelets is taken up by the spleen (and liver) 
17. 
than in normals. 
Our data on patients with ITP who had failed to respond to 
splenectomy indicates that the continued thrombocytopenia in these patients 
may be due to increased destruction in the liver. 
As stated above the findings in patients with splenomegaly support 
the concept of a splenic pool of platelets. 
Hypersplenism or ITP? 
There were three patients studied in whom the results were 
particularly difficult to evaluate. They were three females of greatly 
differing ages who had clinical ITP, but had normal platelet lifespan and 
low spleen /liver ratios and low spleen counts. (See Table 2 and Fig. 9). 
The platelet counts were low and ranged from 10,000 to 40,000. Cohen et 
al (1961) reported four such cases and Aster and Jandl (1964) a further 
one. They reported normal megakaryocytes in the marrow but postulated a 
production deficit. However while this remains a possibility, all of 
our patients had normal or increased megakaryocytes in the marrow. Surface 
counting did not reveal any site of sequestration, and spleen counts were 
low. The condition is therefore not a form of hypersplenism. It is 
possible that infused platelets were treated differently from naturally 
produced platelets due to different antigenic composition, but this seems 
unlikely. If production is normal, and infused platelets survive normally, 
it is possible that the thrombocytopenia is due to a deficit in the platelets 
of the patient. We have a ready comparison in the red cells in the condition 
of spherocytosis. Further studies with DFP or autologous platelets labelled 
with 51Cr are necessary before this condition may be ascribed more definitely 
to a deficit in production. A further possibility is that antibodies act 
only against the megakaryocytes thus causing a deficit in production or 
release, but this is not known to happen in the red cell series and can 
only be another hypothesis. Although gamma globulin has been shown to 
coat megakaryocytes in patients with ITP, in those patients' sera anti - 
platelet antibodies were demonstrated and reduced platelet survival may be 
inferred. 
13. 
Classification of Thrombocytopenias 
Finally in Table 4 a tentative classification of the 
thrombocytopenias is shown. It resemble that proposed by Cohen et al (1961). 
It may need revision and extension in the light of future investigations. 
PLATELET SURVIVAL - SUMMARY 
Methods are described for the in vitro labelling of autologous 
or isologous platelets with sodium 51chromate and the in vivo labelling 
of platelets with di- isopropyl32phosphorofluoridate. Excellent correlation 
has been found in simultaneous application of the two methods. The 
technique used for surface counting over the liver, spleen and praecordium 
is described and the interpretation of surface counting data discussed. 
Essential thrombocythaemia and post -splenectomy thrombocytosis 
are associated with normal platelet survival. The increased platelet 
count in those conditions is therefore ascribed to increased production of 
platelets and not to prolonged platelet lifespan. 
The thrombocytoepnia of hypersplenism is usually associated 
with normal platelet survival and increased surface counts over the spleen. 
The results support the concept that this type of thrombocytopenia is due 
to sequestration of platelets in a splenic platelet pool, the size of which 
is dependent on the amount of splenic tissue. The patients with hyper - 
splenism who were studied include three patients with tropical splenomegaly. 
In two patients with large spleens and reduction in platelet. survival the 
disease causing the splenomegaly was a lymphoproliferative one in which 
abnormal antibodies might be produced. 
In patients with aplastic anaemia the platelet survival is normal. 
Patients with idiopathic thrombocytopenic purpura (ITP) commonly 
show a marked reduction in platelet lifespan, in keeping with the hypothesis 
that this disease has an autoimmune aetiology and the thrombocytopenia is 
due to anti -platelet antibodies. There is a small group of patients with 
clinical ITP in whom the platelet survival is normal. Previously a deficit 
in production of platelets has been suggested as the cause in these patients, 
but in view of the normal or increased numbers of megakaryocytes in the 
marrow, alternative mechanisms for the production of thrombocytopenia are 
discussed. Surface counting data suggests that in patients with ITP a 
greater proportion of injected platelets is taken up by the spleen than 
in normal subjects, and thus far such data has been found in patients who 
have responded to splenectomy. 
In patients with ITP who had failed to respond to splenectomy 
shortened platelet lifespan has been demonstrated, associated with a 
high uptake of injected platelets by the liver. In patients with ITP 
who had remissions after splenectomy or who had their spleens removed 
for other reasons, normal platelet lifespan has been found associated 
with a smaller uptake of injected platelets by the liver. 
In the light of these findings a revised classification of 
the thrombocytopenias is suggested. 
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Table 1 
CONIPARISON OF TWO PLATELET LABELS 
Dl P 
(Di-isopropylphosphorofluoridate) 
Labels in vivo 
Na251Cr04 
(Sodium Chromate) 
In vitro labelling necessary 
p-emitter )5-emitter: allows surface counting 
Preparation and counting of samples Preparation and counting of samples 
difficult easy 
Not possible in severe thrombocyto- Allows use of donor platelets 
penia 
Toxic Not toxic 
Simultaneously can be used as red 
cell label 
Relatively expensive Inexpensive 
Table 2 
STUDIES IN PATIENTS WITH I.T.P. 
Patient Sex A{e Platelet 





S.C. 7 26 30,000 No 4 
W.W. E. 70 15,000 No 1 
R.S. M 14 35,000 No 2 
E.S. F 18 <10,000 No 2 
J.R. F 36 <10,000 No 2 
R.N.* M 13 160,000 No 9 
J.E. M 10 <10,000 No 3 
W.B. M G3 20,000 No 5 
A.A. F 38 40,000 No 10 
M.B. F 78 <10,000 No 10 
M.P. F 7 30,000 No 10 
J.A. M 18 <10,000 Yes 1 
S.J. M 50 40,000 Yes 3 
J.N. F 12 20,000 Yes 2 
M.F. F 33 <10,000 Yes 1 
M.F. F 38 250,000 Yes 10 
W.W. i:1 7C 300,000 Yes 10 
* On steroids 
Table 3 
STUDIES IN PATIENTS WITH HYPERSPLENISM 





A.C. F 6G Reticulum cell sarcoma 100,000 10 
L.C. F 58 Lymphosarcoma 50,000 5 
G.D. IMI 55 Hodgkin's 30,000 5 
M.T. F 36 Polymyositis 50,000 8 
J.W. F 68 Lymphosarcoma 50,000 10 
M.N. F 60 Felty's syndrome 100,000 11 
E.S. F 64 Cirrhosis of liver 80,000 11 
J.M. M 63 Cirrhosis of liver 100,000 10 
J.T. F 61 Cirrhosis of liver 80,000 9 
J.S. M 59 Cirrhosis of liver 110,000 9 
H.M. F 6e Cirrhosis of liver 70,000 8 
A.G. F 60 Cirrhosis of liver 90,000 10 
J.C. Ii 69 Cirrhosis of liver 75,000 9 
P.C. F 71 Cirrhosis of liver. 70,000 10 
G.S. M 26 Spherocytosis 120,000 10 
Kat M 31 Idiopathic tropical 
splenomegaly 
115,000 10 
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